阿尔凯默斯 - Alixorexton在首次给药九个月后,于第24周在MWT和ESS上显示出持续改善

美股速递
Jul 13

阿尔凯默斯公司宣布,其候选药物Alixorexton在首次给药九个月后,于临床试验的第24周评估中,在维持清醒测试和嗜睡量表两项关键指标上均表现出持续性的改善。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10